1H-Imidazolium, 3-ethyl-1-methyl-, chloride (1:1)

Endpoint summary

Description of key information

LD50 (oral, rat): >300 - < 2000 mg/kg bw (BASF, 2006)
LD50 (dermal, rat): > 2000 mg/kg (BASF, 2006)

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion

Endpoint conclusion:

adverse effect observed

Dose descriptor:

LD50

Quality of whole database:

GLP guideline study

Acute toxicity: via inhalation route

Endpoint conclusion

Endpoint conclusion:

no study available

Acute toxicity: via dermal route

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

discriminating dose

Value:

2 000 mg/kg bw

Quality of whole database:

GLP guideline study

Additional information

Oral study

The study was performed to assess the acute toxicity following oral administration of 1-Ethyl-3-methyl-1-imidazolium chloride (EMIM CI) in Wistar rats. Single doses of 2000 and 300 mg/kg body weight of test material preparations in doubly distilled water were given to 3 administration groups of three fasted female animals each, (2000 mg/kg in 3 females, 300 mg/kg in 6 females) by gavage in a sequential manner. Two animals of the 2000 mg/kg administration group were found dead within 1 hour after administration. No mortality occurred in the 300 mg/kg administration groups. Clinical observation in the animals that died of the 2000 mg/kg administration group revealed impaired and poor general state, dyspnoea, lateral position, staggering and tremor. Findings were observed within 0 hour after administration. No clinical signs and findings were observed in the 300 mg/kg administration groups and in the surviving animal of the 2000 mg/kg administration group. The body weight of the surviving animal of the 2000 mg/kg administration group increased during the first post-exposure observation week, but did not adequately increase during the second week. The mean body weights of the 300 mg/kg administration groups increased throughout the study period. No macroscopic pathologic abnormalities were noted in the animals that died and in the surviving animals examined at the end of the observation period. Under the conditions of this study the median lethal dose of 1-Ethyl-3-methyl-1-imidazolium chloride (EMIM CI) after oral administration was found to be greater than 300 mg/kg and less than 2000 mg/kg body weight in rats (BASF, 2006).

Dermal study

The study was performed to assess the acute dermal toxicity of 1-Ethyl-3-methyl-1- imidazolium chloride (EMIM CI) in Wistar rats.

A single dose of 2000 mg/kg body weight of a test material preparation in doubly distilled water was applied in five male and five female animals to the clipped skin (dorsal and dorsolateral parts of the trunk) and covered by a semi-occlusive dressing for 24 hours.

No mortality occurred. No systemic clinical observations or skin effects were noted in the animals. The mean body weights of the animals increased throughout the study period. No macroscopic pathologic abnormalities were noted in the animals examined at the end of the study. Under the conditions of this study, the acute dermal median lethal dose (LD50) of 1-Ethyl-3-

methyl-1-imidazolium chloride (EMIM CI) after dermal application was found to be greater than 2000 mg/kg body weight in male and female rats (BASF, 2006).

Justification for selection of acute toxicity – oral endpoint
only available study

Justification for selection of acute toxicity – dermal endpoint
only available study

Justification for classification or non-classification

Based on the results of the acute toxicity properties, the test item is classified as harmful if swallowed Cat.4 (H302) according to Regulation (EC) No 1272/2008 (CLP).